Abstract:CATSHL syndrome, characterized by camptodactyly, tall stature and hearing loss, is caused by loss-of-function mutations of fibroblast growth factor receptors 3 (FGFR3) gene. Most manifestations of patients with CATSHL syndrome start to develop in the embryonic stage, such as skeletal overgrowth, craniofacial abnormalities, however, the pathogenesis of these phenotypes especially the early maldevelopment remains incompletely understood. Furthermore, there are no effective therapeutic targets for this skeleton dysplasia. Methods: We generated fgfr3 knockout zebrafish by CRISPR/Cas9 technology to study the developmental mechanisms and therapeutic targets of CATSHL syndrome. Several zebrafish transgenic lines labeling osteoblasts and chondrocytes, and live Alizarin red staining were used to analyze the dynamical skeleton development in fgfr3 mutants. Western blotting, whole mount in situ hybridization, Edu labeling based cell proliferation assay and Wnt/beta-catenin signaling antagonist were used to explore the potential mechanisms and therapeutic targets. Results: We found that fgfr3 mutant zebrafish, staring from early development stage, showed craniofacial bone malformation with microcephaly and delayed closure of cranial sutures, chondroma-like lesion and abnormal development of auditory sensory organs, partially resembling the clinical manifestations of patients with CATSHL syndrome. Further studies showed that fgfr3 regulates the patterning and shaping of pharyngeal arches and the timely ossification of craniofacial skeleton. The abnormal development of pharyngeal arch cartilage is related to the augmented hypertrophy and disordered arrangement of chondrocytes, while decreased proliferation, differentiation and mineralization of osteoblasts may be involved in the delayed maturation of skull bones. Furthermore, we revealed that deficiency of fgfr3 leads to enhanced IHH signaling and up-regulated canonical Wnt/beta-catenin signaling, and pharmacological inhibition of Wnt/beta-catenin could partially alleviate the phenotypes of fgfr3 mutants. Conclusions: Our study further reveals some novel phenotypes and underlying developmental mechanism of CATSHL syndrome, which deepens our understanding of the pathogenesis of CATSHL and the role of fgfr3 in skeleton development. Our findings provide evidence that modulation of Wnt/beta-catenin activity could be a potential therapy for CATSHL syndrome and related skeleton diseases.

[Gly374arg Mutation in Fgfr3 Causes Achondroplasia in Mice].

Gly369Cys Mutation in Mouse FGFR3 Causes Achondroplasia by Affecting Both Chondrogenesis and Osteogenesis.

A Lys644Glu Substitution in Fibroblast Growth Factor Receptor 3 (FGFR3) Causes Dwarfism in Mice by Activation of STATs and Ink4 Cell Cycle Inhibitors.

Generation of Fgfr3 Conditional Knockout Mice

A Neonatal Lethal Mutation in FGFR3 Uncouples Proliferation and Differentiation of Growth Plate Chondrocytes in Embryos.

A Ser(365)-->Cys Mutation of Fibroblast Growth Factor Receptor 3 in Mouse Downregulates Ihh/PTHrP Signals and Causes Severe Achondroplasia.

Mouse Models Orthologous to FGFR3-related Skeletal Dysplasias.

Ser217cys Mutation in the Ig Ii Domain of Fgfr3 in A Chinese Family with Autosomal Dominant Achondroplasia

[Detection of Fibroblast Growth Factor Receptor 3 Gene Mutation at Nucleotide 1138 Site in Congenita Achondroplasia Patients].

Defective Lysosomal Targeting of Activated Fibroblast Growth Factor Receptor 3 in Achondroplasia.

A Pro253Arg Mutation in Fibroblast Growth Factor Receptor 2 (fgfr2) Causes Skeleton Malformation Mimicking Human Apert Syndrome by Affecting Both Chondrogenesis and Osteogenesis

Motor deficits in fibroblast growth factor receptor-3 null mutant mice.

FGFR3 Induces Degradation of BMP Type I Receptor to Regulate Skeletal Development.

Heterozygous FGFR3 c.138G>A Mutation Presenting With Achondroplasia and Hemifacial Microsomia

Chinese Achondroplasia is Also Defined by Recurrent G380R Mutations of the Fibroblast Growth Factor Receptor-3 Gene

Gene Mutation in Fetuses with Short Limbs Deformity

Identification of a novel mutation in the FGFR3 gene in a Chinese family with Hypochondroplasia.

<i>Fgfr3</i> mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/-catenin signaling

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.

Optimizing CRISPR/Cas9 Technology for Precise Correction of the Fgfr3-G374R Mutation in Achondroplasia in Mice

Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling